This new resource provides activists with information about two shorter treatment regimens for drug-sensitive TB, and equips them with actions they can take and arguments they can use to advocate for access to those regimens.

October 2021 issue of TAGline delves deep into the development of long-acting formulations for the treatment and prevention of HIV, TB, hepatitis C, and malaria.

Treatment Action Group (TAG) launches newly available TB chapters of its 2021 Pipeline Report.

PLOS ONE publishes TAG’s comprehensive analysis of public investments in the development of rapid technology for diagnosing infectious diseases.

Take a short survey and help evaluate the first 10 years of the Global TB CAB!

Take a quick Community Advisory Board (CAB) compensation survey and help define how to best support CAB members!

The tools are meant to help build awareness of TB in communities, share information on the latest scientific and policy developments, and inform activism to address barriers to TB diagnosis, treatment, and care.

A shorter regimen containing rifapentine and moxifloxacin can cure TB in four months.

TAG and AfroCAB are inviting applications from treatment activists and community leaders for a new cross-disease long-acting technologies community advisory board. The deadline to apply is 21 May 2021.

Treatment Action Group (TAG) is seeking a consultant to advance strategic policy-advocacy and resource mobilization efforts for TB research and development (R&D) in the context of the European Union (EU) and UK global development cooperation.